DK1893587T3 - Fremgangsmåde til fremstilling af dihydroquinazoliner - Google Patents

Fremgangsmåde til fremstilling af dihydroquinazoliner

Info

Publication number
DK1893587T3
DK1893587T3 DK06743106.4T DK06743106T DK1893587T3 DK 1893587 T3 DK1893587 T3 DK 1893587T3 DK 06743106 T DK06743106 T DK 06743106T DK 1893587 T3 DK1893587 T3 DK 1893587T3
Authority
DK
Denmark
Prior art keywords
dihydroquinazolines
preparation
dihydroquinalzolines
useful
formula
Prior art date
Application number
DK06743106.4T
Other languages
English (en)
Inventor
Oliver Kuhn
Kaethe Goossen
Mathias Berwe
Joachim Krueger
Hans-Christian Militzer
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Application granted granted Critical
Publication of DK1893587T3 publication Critical patent/DK1893587T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK06743106.4T 2005-06-15 2006-06-02 Fremgangsmåde til fremstilling af dihydroquinazoliner DK1893587T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005027517A DE102005027517A1 (de) 2005-06-15 2005-06-15 Verfahren zur Herstellung von Dihydrochinazolinen
PCT/EP2006/005298 WO2006133822A1 (de) 2005-06-15 2006-06-02 Verfahren zur herstellung von dihydrochinazolinen

Publications (1)

Publication Number Publication Date
DK1893587T3 true DK1893587T3 (da) 2012-05-07

Family

ID=36764739

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06743106.4T DK1893587T3 (da) 2005-06-15 2006-06-02 Fremgangsmåde til fremstilling af dihydroquinazoliner

Country Status (23)

Country Link
US (3) US8084604B2 (da)
EP (1) EP1893587B1 (da)
JP (1) JP5114391B2 (da)
KR (1) KR101355229B1 (da)
CN (2) CN101213180B (da)
AT (1) ATE542803T1 (da)
AU (1) AU2006257415B2 (da)
BR (1) BRPI0613277B1 (da)
CA (1) CA2611927C (da)
DE (1) DE102005027517A1 (da)
DK (1) DK1893587T3 (da)
ES (1) ES2383989T3 (da)
HR (1) HRP20120319T1 (da)
IL (1) IL187586A (da)
MX (1) MX2007016040A (da)
NO (1) NO340521B1 (da)
NZ (1) NZ564325A (da)
PL (1) PL1893587T3 (da)
PT (1) PT1893587E (da)
RU (1) RU2419617C2 (da)
SI (1) SI1893587T1 (da)
WO (1) WO2006133822A1 (da)
ZA (1) ZA200710481B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) * 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
CN103232400B (zh) * 2013-04-26 2015-01-21 苏州大学 一种制备喹唑啉-2-硫酮的方法
CN120097924A (zh) * 2013-06-19 2025-06-06 Aic246股份两合公司 无定形莱特莫韦及其用于口服施用的固体药物制剂
WO2015088931A1 (en) * 2013-12-12 2015-06-18 Merck Sharp & Dohme Corp. Process for making substituted quinazoline compounds
WO2016109360A1 (en) * 2014-12-29 2016-07-07 Auspex Pharmaceuticals, Inc. Dihydroquinazoline inhibitors of viral terminase
WO2017091453A1 (en) * 2015-11-24 2017-06-01 Merck Sharp & Dohme Corp. Novel processes for making substituted quinazoline compounds using hydrogen bonding catalysts
CN111024861A (zh) * 2019-12-31 2020-04-17 山东省药学科学院 一种莱特莫韦及含莱特莫韦的制剂中有关物质的检测方法
PY2116987A (es) 2020-02-27 2021-12-01 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso
PY2116973A (es) 2020-02-27 2021-11-18 Aic246 Gmbh & Co Kg Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
IT202000017617A1 (it) * 2020-07-21 2022-01-21 Olon Spa Procedimento per la preparazione di un intermedio utilizzato nella sintesi del letermovir
US20230312485A1 (en) 2020-08-17 2023-10-05 Lupin Limited A precipitation process for amorphous letermovir
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
WO2023185597A1 (zh) * 2022-04-01 2023-10-05 上海迪赛诺化学制药有限公司 莱特莫韦中间体及其制备方法
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
WO2024037485A1 (zh) * 2022-08-15 2024-02-22 上海迪赛诺化学制药有限公司 一种来特莫韦无定形的制备方法
CN115677539B (zh) * 2022-11-01 2023-10-24 南京工业大学 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法
CN115974793B (zh) * 2022-12-23 2025-01-28 浙江车头制药股份有限公司 一种来特莫韦中间体拆分副产物的消旋回收方法
CN115947694B (zh) * 2023-01-10 2025-12-19 云南大学 一种二氢喹唑啉化合物的制备方法
CN116874436B (zh) * 2023-07-11 2025-08-08 济宁学院 一种来特莫韦中间体的制备方法
CN117486808A (zh) * 2023-11-06 2024-02-02 北京康立生医药技术开发有限公司 一种来特莫韦关键中间体新的制备方法
CN117658928A (zh) * 2023-11-07 2024-03-08 北京康立生医药技术开发有限公司 一种预防cmv感染药物中间体新的制备方法
WO2025133248A1 (en) 2023-12-21 2025-06-26 Aic246 Ag & Co. Kg Diastereomeric aminoalcohol and aminoether salts of 2-[(4r,s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl]acetic acid and their use for enantiomeric separation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
JP2002503662A (ja) 1998-02-17 2002-02-05 テュラリク インコーポレイテッド 抗ウイルス性ピリミジン誘導体
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DE60113865T2 (de) 2000-07-31 2006-07-20 Vernalis Research Ltd., Winnersh Piperazin derivate
EP1201765A3 (en) 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
DE10251914A1 (de) 2002-11-08 2004-05-19 Bayer Ag Substituierte Chinazoline
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
KR100610731B1 (ko) 2004-02-24 2006-08-09 한국과학기술연구원 T-형 칼슘 채널 차단제로서 유용한 3,4-디히드로퀴나졸린유도체 및 그의 제조 방법
DE102004022672A1 (de) 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
NZ560320A (en) 2005-01-25 2011-02-25 Prolexys Pharmaceuticals Inc Quinoxaline derivatives as antitumor agents
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
WO2007009911A1 (en) 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS

Also Published As

Publication number Publication date
KR101355229B1 (ko) 2014-01-27
ES2383989T3 (es) 2012-06-28
ATE542803T1 (de) 2012-02-15
BRPI0613277A2 (pt) 2010-12-28
JP5114391B2 (ja) 2013-01-09
AU2006257415B2 (en) 2011-11-24
NO20080129L (no) 2008-01-08
PT1893587E (pt) 2012-05-07
NZ564325A (en) 2010-11-26
EP1893587B1 (de) 2012-01-25
CN101213180A (zh) 2008-07-02
HRP20120319T1 (hr) 2012-05-31
BRPI0613277B1 (pt) 2022-01-25
DE102005027517A1 (de) 2006-12-21
RU2007147955A (ru) 2009-07-20
CN101863843B (zh) 2013-03-27
CN101863843A (zh) 2010-10-20
NO340521B1 (no) 2017-05-02
KR20080031278A (ko) 2008-04-08
JP2008543797A (ja) 2008-12-04
CN101213180B (zh) 2011-09-07
SI1893587T1 (sl) 2012-10-30
ZA200710481B (en) 2009-08-26
CA2611927C (en) 2013-10-22
HK1116185A1 (en) 2008-12-19
US20120130072A1 (en) 2012-05-24
EP1893587A1 (de) 2008-03-05
US8816075B2 (en) 2014-08-26
RU2419617C2 (ru) 2011-05-27
CA2611927A1 (en) 2006-12-21
IL187586A (en) 2013-07-31
WO2006133822A1 (de) 2006-12-21
US8372972B2 (en) 2013-02-12
US20090221822A1 (en) 2009-09-03
PL1893587T3 (pl) 2012-06-29
US8084604B2 (en) 2011-12-27
AU2006257415A1 (en) 2006-12-21
IL187586A0 (en) 2008-03-20
US20130066073A1 (en) 2013-03-14
MX2007016040A (es) 2008-03-10

Similar Documents

Publication Publication Date Title
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
MY152114A (en) Novel pyrazole-4-n-alkoxycarboxamides as microbiocides
EA200901609A1 (ru) Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов
EA201170132A1 (ru) 5-гетероциклилалкил-3-гидрокси-2-фенилциклопент-2-еноны в качестве гербицидов
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
TN2010000064A1 (en) Novel herbicides
MX2010001364A (es) Derivados de ciclopentandiona puenteados triciclicos como herbicidas.
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
UA102289C2 (ru) Гербициды, полученные из циклопентадиона
UA106880C2 (uk) Нові гербіциди
WO2008151828A8 (en) Novel microbiocides
TN2011000355A1 (en) Novel microbiocides
WO2009127718A3 (en) Novel microbiocides
WO2009003672A3 (en) Novel microbiocides
NO20081207L (no) Isoquinolines as IGF-1R inhibitors
TW200800969A (en) Compounds
DE602006009789D1 (de) Acetylenderivate
TN2010000094A1 (en) Novel herbicides
NO20074528L (no) Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme
IN2012DN01223A (da)
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors